MRCK beta Antibody (Y-2D13): sc-134392
- MRCKβ Antibody (Y-2D13) is a mouse monoclonal IgG2a κ provided at 100 µg/ml
- raised against recombinant MRCKβ protein of human origin
- recommended for detection of MRCKβ of human origin by WB, IP, IF, IHC(P) and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for MRCKβ Antibody (Y-2D13). This work is in progress.
QUICK LINKS
MRCKβ Antibody (Y-2D13) is a mouse monoclonal IgG2a antibody that detects MRCKβ in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). MRCKβ, a member of the myotonic dystrophy kinase-related Cdc42-binding kinases family, plays a crucial role in regulating actin dynamics and cellular motility by phosphorylating nonmuscle myosin light chains, which in turn influences actin-myosin contractility. MRCKβ is primarily located in the cytoplasm, where MRCKβ activity is essential for processes such as cell migration and neurite outgrowth, both of which are vital for proper development and tissue repair. The presence of a cysteine-rich motif and a pleckstrin homology domain in MRCKβ suggests involvement in signaling pathways that respond to cellular cues, making MRCKβ a key player in the orchestration of cytoskeletal rearrangements. Anti-MRCKβ antibody (Y-2D13) enables researchers to gain insights into the mechanisms of cell motility and the underlying pathophysiology of diseases associated with cytoskeletal dysfunction.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
MRCK beta Antibody (Y-2D13) References:
- The CDC42 effector protein MRCKβ autophosphorylates on Threonine 1108. | Unbekandt, M., et al. 2020. Small GTPases. 11: 451-460. PMID: 30667325
- Regulation of Cdc42 and its effectors in epithelial morphogenesis. | Pichaud, F., et al. 2019. J Cell Sci. 132: PMID: 31113848
- De novo heterozygous missense and loss-of-function variants in CDC42BPB are associated with a neurodevelopmental phenotype. | Chilton, I., et al. 2020. Am J Med Genet A. 182: 962-973. PMID: 32031333
- MRCKα Is Dispensable for Breast Cancer Development in the MMTV-PyMT Model. | Kwa, MQ., et al. 2021. Cells. 10: PMID: 33921698
- MRCKβ links Dasm1 to actin rearrangements to promote dendrite development. | Wang, XX., et al. 2021. J Biol Chem. 296: 100730. PMID: 33933448
- Spatiotemporal control of actomyosin contractility by MRCKβ signaling drives phagocytosis. | Zihni, C., et al. 2022. J Cell Biol. 221: PMID: 36121394
- Opportunities and Challenges for the Development of MRCK Kinases Inhibitors as Potential Cancer Chemotherapeutics. | Ruscetta, VM., et al. 2023. Cells. 12: PMID: 36831201
- MRCKα/β positively regulates Gli protein activity. | Baran, B., et al. 2023. Cell Signal. 107: 110666. PMID: 37019250
- Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK. | Wu, Q., et al. 2023. J Ethnopharmacol. 315: 116644. PMID: 37196814
- Characterization of Anticancer Effects of the Analogs of DJ4, a Novel Selective Inhibitor of ROCK and MRCK Kinases. | Kale, VP., et al. 2023. Pharmaceuticals (Basel). 16: PMID: 37630974
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MRCKβ Antibody (Y-2D13) | sc-134392 | 100 µg/ml | $339.00 |